中樞神經系統的藥物開發：睡眠障礙

中樞神經系統的藥物開發：睡眠障礙 是由出版商Espicom Business Intelligence在2006年11月所出版的。 這份英文市場調查報告書包含82 Pages 價格從美金1625起跳。

簡介

目錄

Abstract

This chapter of CNS Drug Discoveries focuses on the developments in the insomnia market and the substantial changes beginning to take place.

The insomnia market is a maturing market and we believe the landscape will change dramatically over the next five years as the market enters a transition phase and becomes more fragmented. We forecast it will grow to nearly US$6 billion by 2012 driven by a number of factors including the launch of new formulations, new drug classes, patient dynamics (ageing patient population) and changes in the way insomnia is treated.

Sleep disorders cover a range of problems, the best known types being insomnia, sleep apnoea and restless legs syndrome. Insomnia is the most prevalent sleep disorder and it is estimated to affect over 37 million US citizens and over 100 million people worldwide with approximately 25% of elderly people and 15% of the general population suffering from the condition. Studies suggest that less than 20% of insomniacs seek help and less than 20% of sufferers are prescribed a medication from their doctor.

Global insomnia market Approximately US$2.4 billion is currently spent on hypnotics and sedatives in the treatment of insomnia, the 10th largest segment of CNS drug sales. The global market for insomnia drugs is unevenly distributed. In 2005, the US insomnia market accounted for 66% of the global market compared to 24% in Europe and 10% in the rest of world (largely Japan). This is mainly due to the pricing differential between the European and the US market.

GABA-A receptor agonists (non-benzodiazepines) continue to remain the cornerstone for the treatment of both acute and chronic insomnia. However, the launch of several new products over the next 3 years will help to increase patient awareness, particularly in the elderly.

Table of Contents

INSOMNIA

• EXECUTIVE SUMMARY
• THE FACTS
  • What is insomnia and why are we interested in it?
• PATIENT STATISTICS
  • Summary of insomnia patient population in top 5 European countries
• PATIENT MODEL
  • The addressable insomnia market will have a CAGR 2005-2012 = 5.9%
    • Patient population and sub-types of insomnia
    • Summary of patient population (for top seven countries) forecasts
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPNERS

GLOBAL INSOMNIA MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • US market
    • Insomnia US drugs sales split (2005A)
  • European market
    • Insomnia European drugs sales split (2005A)
  • Japanese market
    • Insomnia Japanese drugs sales split (2005A)
  • The major players
    • Market share of insomnia players by sales (Dec 2005A)
  • Players and Products in 2005
  • Players and Products in 2012
    • Market share of insomnia players by sales (Dec 2012E)
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of Leading Brands
  • Current Products Patent Exposure
    • Patent exposure of leading brands
• ANALYSIS OF LEADING BRANDS
  • GABA-A Receptor Agonists
  • Melatonin Receptor Agonist
• GABA-A Receptor Agonists
  • Ambien/Stilnox/Myslee and Ambien CR (sanofi-aventis)
  • Lunesta (Sepracor)
  • Sonata (King Pharmaceuticals)
• Melatonin Receptor Agonist
  • Rozerem (Takeda)
    • Distribution of ML-1 and ML-2 receptors
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading Insomnia Drugs (US$ million)
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat Insomnia
• ANALYSIS OF PHASE III DRUGS
  • Drugs in Phase III Development to Treat Insomnia
  • GABA-A Receptor Agonists
  • Histamine Receptor Antagonist
  • 5-HT2A Receptor Antagonist
  • Melatonin Receptor Agonist
  • indiplon (Neurocrine Biosciences)
  • gaboxadol (Lundbeck)
  • Silenor (Somaxon)
  • Eplivanserin (sanofi-aventis)
    • Effect of eplivanserin on sleep parameters in Phase IIb trial
  • VEC-162 (Vanda Pharmaceuticals)
    • Efficacy of VEC-162 in transient insomnia trials
• GLOBAL SALES FORECASTS OF PHASE III INSOMNIA DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental Insomnia Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat Insomnia
  • 5-HT2A Receptor Antagonists
  • GABA-A Receptor Modulator
  • Melatonin Analogue
• 5-HT2A RECEPTOR ANTAGONISTS
  • M100907 (sanofi-aventis)
  • Pruvanserin (Eli Lilly)
• GABA-A MODULATORS
  • NG2-73 (Neurogen)
• MELATONIN ANALOGUE
  • PD-6735 (Phase II Discovery)
• GLOBAL SALES FORECASTS OF PHASE II INSOMNIA DRUGS 2006 - 2012
  • Sales Forecasts of Insomnia Drugs in Phase III
  • Model assumptions
    • CR Analysis of Insomnia Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of Insomnia Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the Insomnia Market by 2012
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
• INSOMNIA APPENDIX 1
  • Analysis of clinical trial data
• INSOMNIA APPENDIX 2
  • Phase transition probability
    • Probability of launch
• INSOMNIA APPENDIX 3
  • Patient Model
    • Summary of US Insomnia Patient Population Forecasts
    • Summary of Europe (Top 5) Insomnia Patient Population Forecasts
    • Summary of Japan Insomnia Patient Population Forecasts
• INSOMNIA APPENDIX 4
  • Global Drug Sales 2005-2012 (US$ million)
• INSOMNIA APPENDIX 5
  • Competitor Ratio Analysis Criteria
    • Key insomnia drugs due to be launched by 2012
• INSOMNIA GLOSSARY
• INSOMNIA REFERENCES
• Acronyms

相關商品

藥物開發相關市場調查報告書

分析工具：癌症治療的蛋白激脢抗化劑
Analytical Tool - Protein Kinase Inhibitors in Oncology
價格 : US $ 6674
出版日期 : 2012年05月

乳癌，肺癌，Protein Kinase抗化劑:藥物開發策略分析
Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

白血病，肺癌，Protein Kinase抗化劑:藥物開發策略分析
Triple Analysis: Leukemia, Lung Cancer and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

Espicom Business Intelligence發行的製藥相關市場調查報告書

中國的不同地區的醫療市場

Understanding Regional Chinese Health Markets

價格 : US $ 690

出版日期 : 2012年03月

全球學名藥市場:2012年

The World Generic Market Report 2012

價格 : US $ 1390

出版日期 : 2012年03月

北歐地區藥品市場發展前景

The Outlook for Pharmaceuticals in Northern Europe

價格 : US $ 3630

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!